Compare EB & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EB | TRDA |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.7M | 386.8M |
| IPO Year | 2018 | 2021 |
| Metric | EB | TRDA |
|---|---|---|
| Price | $4.43 | $11.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.7M | 216.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $294,798,000.00 | $61,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | $3.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.81 | $4.93 |
| 52 Week High | $4.46 | $18.96 |
| Indicator | EB | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 84.03 | 70.29 |
| Support Level | $2.44 | $10.82 |
| Resistance Level | $4.46 | $11.24 |
| Average True Range (ATR) | 0.02 | 0.54 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 98.77 | 82.70 |
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. The company's two-sided marketplace connects creators and consumers every month to share their passions, artistry, and causes through live experiences. Creators use its self-service ticketing and marketing tools to plan, promote, and sell tickets to their events, and event seekers use its website and mobile application to discover and purchase tickets to experiences. Geographically, it generates maximum revenue from the United States. The company generates revenues principally from service fees and payment processing fees from the sale of paid tickets on its platform.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.